Study: Copanlisib + rituximab slows relapsed indolent lymphoma
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2